2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry

Munafò, Andrea; Scotti, Andrea; Estévez‐Loureiro, Rodrigo; Adamo, Marianna; Hernández, Antonio Portolés; Peregrina, Estefanía Fernández; Gutiérrez, Laura; Taramasso, Maurizio; Fam, Neil; Ho, Edwin; Asgar, Anita W.; Vitrella, Giancarlo; Raineri, Claudia; Chizzola, Giuliano; Pezzola, Elisa; Ruz, Robin Le; Montalto, Claudio; Oreglia, Jacopo; Fraccaro, Chiara; Giannini, Cristina; Fiorelli, Francesca; Rubbio, Antonio Popolo; Ooms, Joris F.; Compagnone, Miriam; Marcelli, Chiara; Maffeo, Diego; Bettari, Luca; Fürholz, Monika; Arzamendi, Dabit; Guérin, Patrice; Tamburino, Corrado; Petronio, Anna Sonia; Grasso, Carmelo; Agricola, Eustachio; Mieghem, Nicolás M. Van; Tarantini, Giuseppe; Praz, Fabien; Pascual, Isaac; Potena, Luciano; Colombo, Antonio; Metra, Marco; Margonato, Alberto; Saia, Francesco; Godino, Cosmo

doi:10.1016/j.ijcard.2023.131139

Cited by 7 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially in these highest-risk patients with cardiogenic shock, new therapeutic approaches are needed to ameliorate the dismal outcome. Registry data showed that M-TEER is a potentially effective bridge-to-transplant strategy in selected patients [ 42 ]. A considerable percentage of 22.5% of patients no longer had an indication for heart transplantation because of significant clinical improvement after M-TEER [ 42 ].…”

Section: 10 Challenges Of M-teermentioning

confidence: 99%

See 1 more Smart Citation

Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair

Orban,

Weckbach,

Stocker

et al. 2024

JCM

View full text Add to dashboard Cite

Mitral valve transcatheter edge-to-edge repair (M-TEER) and replacement (TMVR) have evolved as guideline-recommended treatment approaches for mitral regurgitation (MR). Even though they are supported by a growing body of evidence from either randomized trials or large registries, there are still several unsolved challenges in the field of interventional MR treatment. In the present review, we discuss the ten most important open questions regarding M-TEER and TMVR.

show abstract

Section: 10 Challenges Of M-teermentioning

confidence: 99%

“…Registry data showed that M-TEER is a potentially effective bridge-to-transplant strategy in selected patients [ 42 ]. A considerable percentage of 22.5% of patients no longer had an indication for heart transplantation because of significant clinical improvement after M-TEER [ 42 ].…”

Section: 10 Challenges Of M-teermentioning

confidence: 99%

Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair

Orban,

Weckbach,

Stocker

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Management of acute decompensated valvular heart disease

Lüsebrink,

Lanz,

Kellnar

et al. 2024

European J of Heart Fail

View full text Add to dashboard Cite

Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock. Current evidence remains scarce and recommendations regarding the management of acute heart failure caused by VHD are lacking in most recent international guidelines. Herein, we review the management of acute heart failure caused by VHD with a focus on transcatheter therapies and describe currently available evidence based on a systematic literature search on the following valve pathologies: (i) aortic stenosis, (ii) aortic regurgitation, (iii) mitral regurgitation, and (iv) mitral stenosis. Articles reporting outcomes following urgent or emergent valve intervention in the setting of cardiogenic shock or acute heart failure were considered. After screening a total of 2234 articles, 76 published between 1994 and 2023 were included in subsequent analysis. Based on available evidence, proposed treatment algorithms to guide optimal management of acute heart failure caused by VHD were created. As the number of patients presenting with acute heart failure caused by VHD continues to rise and outcomes following transcatheter valve interventions continue to improve, it is inevitable that minimally invasive options will play an increasingly important role in the acute setting, especially given these patients are at an increased operative risk. This review aims to present an organized approach to the complex management and interventional treatment of patients with acute heart failure caused by VHD.

show abstract

Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair

Magni,

Adamo,

Pezzola

et al. 2024

Clin Res Cardiol

View full text Add to dashboard Cite

Background To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER). Methods and results Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09–2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32–0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46–0.78; p < 0.001; p = 0.778 for interaction). Conclusions Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity. Graphical Abstract

show abstract

2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry

Cited by 7 publications

References 28 publications

Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair

Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair

Management of acute decompensated valvular heart disease

Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair

Contact Info

Product

Resources

About